Third Rock Ventures
Boston · Seed–Series C · 62 people tracked
Investment thesis
Third Rock Ventures focuses on creating and investing in life sciences and healthcare companies. The firm works with scientific founders and entrepreneurs to launch and build transformative therapeutics, medical devices, and precision medicine platforms, with a demonstrated track record of successful exits including acquisitions by major pharmaceutical and healthcare companies.
Source: firm website, verified Jul 17, 2026.
Team · 62 people
from the firm's websiteInvestments · 10 tracked
- Agios Pharmaceuticals
- Azalea Therapeutics
- Candid Therapeutics
- Decibel Therapeutics
- Element Science
- Merida Biosciences
- Synnovation Therapeutics
- Syremis Therapeutics
- Tango Therapeutics
- Taris Bio
Frequently asked questions
- What stage does Third Rock Ventures invest at?
- Third Rock Ventures invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Third Rock Ventures focus on?
- Third Rock Ventures focuses on Biotech, Digital Health, Medical Devices.
- Where is Third Rock Ventures located?
- Third Rock Ventures is headquartered in Boston, US.
Similar investors
A deep technology venture capital firm investing in companies solving major global challenges across climate change, human health, defense, security, space, and physically intensive industries.
Medicxi is a venture capital firm focused on life sciences and healthcare innovation, supporting biotech and medtech companies through their development and commercialization phases.
EQT Life Sciences, formerly known as LSP, is one of Europe's largest life sciences investors with a 30-year track record. The firm targets innovative companies developing therapeutics, medical devices, diagnostics, and healthtech solutions globally, backed by a team of experienced medical, scientific, and industry professionals.
An early-stage venture capital firm focused on identifying and investing in founders across diverse technology and innovation sectors.
Osage University Partners invests in breakthrough startups emerging from leading research labs and innovation ecosystems, with a focus on tech and life science companies. The firm manages $800 million and has 150+ portfolio companies across all investment stages from pre-seed to crossover.